Skip to main content
Communication

Milestone: PanTum Detect® part of HanseMerkur early detection programme Krebs-Scan

Origem Medical’s consultancy SWYTCH has successfully advised and supported its client Zyagnum AG in the integration of Zyagnum’s blood test PanTum Detect® into the HanseMerkur Insurance Group’s early detection programme Cancer Scan.

We are very pleased for and with Zyagnum AG about the achievement of this milestone.

SWYTCH has been advising Zyagnum AG extensively for many years in the areas of corporate strategy, communications, marketing, PR and internationalisation.

The HanseMerkur Insurance Group successfully launched the cancer screening programme Krebs-Scan, which combines Zyagnum AG’s PanTum Detect® blood test with the strengths of imaging methods (PET/CT and MRI).

More than half a million people in Germany are newly diagnosed with cancer every year. For over 55% of these new cancer cases, however, there is currently no regular early detection. Cancer Scan aims to close this screening gap. A large-scale study at the University Medical Centre Hamburg-Eppendorf (UKE) with over 5,000 participants was able to prove the effectiveness of this procedure.

PanTum Detect® detects the enzymes TKTL1 and DNaseX (Apo10), which are already produced by many tumours in early, symptomless phases. If PanTum Detect® provides an initial suspicion, this is clarified in a second step within the cancer scan programme using the most modern imaging methods.

In this way, a large number of cancers or precancerous lesions can be detected particularly early. This is particularly important because, as a rule, the earlier cancers are detected, the better their chances of being cured.

It makes us proud and grateful to be able to accompany Zyagnum AG as SWYTCH in this so important task and we look forward to further cooperation.

 

For more information on Cancer Scan and PanTum Detect®, please click here:
www.hansemerkur.de/krebs-scan
www.pantumdetect.com

 

About Zyagnum:
Zyagnum AG, a biotechnology company based in Darmstadt, Germany, develops diagnostic solutions for human medicine. Zyagnum has a profound understanding of immunological processes and their connection with diseases. For example, the EDIM® technology developed by Zyagnum can be used in blood tests to detect specific antigens in immune cells that may play a role in tumour development. The company currently employs 33 people and was founded by Zyagnum CEO Ralf Schierl together with Johannes Coy in 2007.

https://www.zyagnum.com

Weitere News

RegioHealth Origem Medical

BIOBALANCE becomes an acceptance partner within the RegioHealth network

| Nutritional diagnostics | No Comments
Our ORIGEM Group company BIOBALANCE is expanding its presence in workplace health promotion and has concluded another important partnership. Since June 2024, BIOBALANCE has been an acceptance partner of the…

BIOBALANCE becomes part of the Wir für Gesundheit benefits program

| Nutritional diagnostics | No Comments
Since May 1, 2024, our ORIGEM group company BIOBALANCE is part of the Wir für Gesundheit benefits program. Wir für Gesundheit (WfG) is the largest German quality network for health.…
Reformhaus

Ideal partners: Origem Medical and Reformhaus® launch collaboration

| Nutritional diagnostics | No Comments
The future of health is personalised. One of the most important and at the same time the most underestimated lever of health is nutrition. This is Origem Medical's DNA and…

Cell Essentials and Prof. Dietrich Grönemeyer agree on close cooperation

| Health Products | No Comments
The newly founded Origem subsidiary Cell Essentials and Prof. Dietrich Grönemeyer (71) want to work closely together and jointly shape the future of personalized health and prevention. "A groundbreaking partnership…